Merck Recommends Rejection Of TRC Capital's "Mini-Tender" Offer To Purchase Up To 1M Shares Of Common Stock At $96.38 Per Share
Merck Recommends Rejection Of TRC Capital's "Mini-Tender" Offer To Purchase Up To 1M Shares Of Common Stock At $96.38 Per Share
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited "mini-tender" offer, dated November 12, 2024, to purchase up to 1,000,000 shares of Merck common stock at $96.38 per share. The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024 ($100.73), the last trading day before the date of the offer, and approximately 3.48% below the closing price of the Merck common stock on November 21, 2024 ($99.86), the day prior to this release.
默沙東（紐交所：MRK），在美國和加拿大以外被稱爲MSD，已收到通知，TRC資本投資公司（TRC Capital）於2024年11月12日發起了一項未經請求的"迷你收購"要約，擬以每股96.38美元購買最多1,000,000股默沙東普通股。該要約價格大約低於2024年11月11日默沙東普通股的收盤價4.32%（100.73美元），這是該要約發佈前的最後交易日，並且大約低於2024年11月21日默沙東普通股的收盤價3.48%（99.86美元），這是本公告發布前一天。
Merck does not endorse TRC Capital's offer and recommends that Merck shareholders reject the offer and not tender their shares in response to TRC Capital's unsolicited mini-tender offer. This mini-tender offer is at a price below the closing price for Merck's shares (as of the day prior to this release) and is subject to numerous conditions, including TRC Capital's ability to obtain financing. Merck is not associated in any way with TRC Capital, its mini-tender offer or the offer documentation.
默沙東不支持TRC資本的要約，並建議默沙東股東拒絕該要約，不要根據TRC資本的未經請求的迷你收購要約進行股份投標。該迷你收購要約的價格低於默沙東股份的收盤價（截至本公告前一天），並受多項條件的限制，包括TRC資本獲得融資的能力。默沙東與TRC資本、其迷你收購要約或要約文件沒有任何關聯。
譯文內容由第三人軟體翻譯。
